CBSC secures Health Canada license for CardioHolter AT with $375K order from Your Heart Protector Corp, expanding cardiac monitoring in Canada.

Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT

CBSC secures Health Canada license for CardioHolter AT, lands $375K order with Your Heart Protector Corp, expanding into Canadian market.
CBSC announces $375,000 Noventis Medical purchase order and new recurring revenue program for MyCardia AT cardiac monitoring devices.

CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical

CBSC secures $375K purchase order with Noventis Medical and launches recurring revenue program for MyCardia AT devices.
Cardiac Biotech Solutions signs exclusive $600K Noventis Medical distribution agreement for Latin America.

Cardiac Biotech Solutions, Inc. (CBSC) Signs Exclusive 5-Year Distribution Agreement with Noventis Medical Covering Costa Rica, Panama, Colombia, and Argentina

Cardiac Biotech Solutions, Inc. signs $600K exclusive distribution deal with Noventis Medical, expanding cardiac monitoring reach into Latin America.

Officially Launches Next-Generation MyCardia AT Cardiac Monitor

CB Scientific, Inc. (CBSC) has officially launched its next-generation MyCardia AT cardiac event monitor in collaboration with Datrix, LLC. Designed for enhanced remote cardiac monitoring, the FDA-cleared device offers a lightweight, easy-to-use design with seamless integration into the MyCardia app ecosystem. The MyCardia AT monitor enables early detection of cardiac arrhythmias, helping physicians diagnose transient heart conditions more effectively. The device is set to roll out across SE Asia, Hong Kong, Macau, and pending regulatory approvals, Canada and China.

How can we help you?

Get our news in your inbox!

Join our newsletter and we will send our news directly to you.